eXmoor Pharma Strengthens Leadership Team with New CEO Appointment

Bristol, UK, July 8, 2025 – We are pleased to announce a change to our leadership structure that reflects eXmoor Pharma’s ongoing commitment to client focus, technical depth and industry leadership.

Angela Osborne, founder of eXmoor Pharma, will step into the newly created role of Executive Chair and interim Chief Commercial Officer. Angela has built the company’s reputation on delivering scientific and operational excellence for clients, and this commitment remains unchanged. She will continue to play an active role in client projects, including participating in steering committees to uphold delivery standards and ensure strategic alignment.
In her new role, Angela will dedicate more time to working directly with clients, bringing her extensive cell and gene therapy (CGT) expertise to support their commercial and development strategies. Her technical insight and sector experience remain central to our mission of helping CGT developers bring therapies to patients faster.

Lucy Foley has been appointed as Chief Executive Officer. Lucy joined eXmoor in 2022 as Chief Technical Officer and brings more than 15 years of experience in biologics and advanced therapy manufacturing. She has held senior roles across the UK life sciences ecosystem, including leading the UK’s RNA Centre of Excellence as part of the national vaccines response and as Director of Biologics at the Centre for Process Innovation (CPI). Her appointment as CEO reflects not only her deep technical leadership but also her longstanding connection with eXmoor and commitment to the sector.

“It’s a privilege to take on this role at a company that values trust, scientific excellence and partnership. I’ve worked closely with Angela for many years and share her commitment to ensuring eXmoor remains a client-first organisation that helps therapies reach patients faster.”

Lucy Foley

CEO

Lucy and Angela co-founded the Advanced Therapy Medicinal Products (ATMP) Manufacturing Community (AMC) in 2010, a not-for-profit network focused on building best practice in CGT manufacturing. The AMC has grown to over 400 members and remains a respected forum for collaboration between academia, industry and regulators. Lucy also currently serves as Vice Chair of the BioIndustry Association’s (BIA) Manufacturing Advisory Committee (MAC), helping shape the future of UK biomanufacturing and representing the voice of the industry at national level.

This leadership evolution reflects our strengths as a consultancy-integrated CDMO:

• A continued focus on client partnership and technical excellence
• Leadership with sector-wide credibility and a track record of impact
• Ongoing investment in scalable, collaborative, and strategic support for our clients

At eXmoor, women make up 54% of our total workforce, and more than half of our senior leadership team are women. This transition reflects our ongoing commitment to championing gender representation in STEM and ensuring diverse voices shape the future of cell and gene therapy manufacturing.

If you have any questions or would like to learn more about our services, please get in touch.

For media enquiries, please contact:

Suzanna Muggleton, IB Comms

[email protected]